This CME Activity has expired and is no longer available for credit.
Module 5: Assessment and Treatment Decisions in HIV/HCV Co-Infection
Time to Complete
April 20, 2018
April 20, 2019
This is Module 5 in the HealthHIV HIV Primary Care Training and Certificate Program.
1.00 / AMA PRA Category 1 CreditTM
This activity is jointly provided by Postgraduate Institute for Medicine and HealthHIV.
This activity is not supported by educational grants.
People with HIV infection are disproportionately affected by viral hepatitis. The CDC reports that in the United States, 25% of people living with HIV are co-infected with hepatitis C virus (HCV), and about 10% are co-infected with hepatitis B virus (HBV).
HCV co-infection is responsible for a five-fold increase in hospitalizations and has become a leading cause of complications and morality among people with HIV.
To better manage the risk of viral hepatitis in this population, people with HIV should be screened for HCV infection annually and before starting antiretroviral therapy (ART).1,2
HIV/HCV co-infections can be effectively managed in many people, but treatment is complex.
In this activity, you will learn how to how effectively identify at-risk patients and screen for HCV co-infection, select appropriate treatment plans, and gain a better understanding of the recommended guidelines for treating and managing HIV/HCV co-infection.
Module 5 of HealthHIV’s HIV Primary Care Training and Certificate Program is designed to build upon previous modules deepening primary care providers’ understanding of HIV epidemiology, diagnosis, and management by familiarizing them with recommended guidelines for treating and managing HIV/HCV co-infection.
This activity has been designed to meet the educational needs of primary care physicians, and other allied healthcare professionals who treat and care for patients with HIV/AIDS.
After completing this activity, the participant will demonstrate the ability to:
Identify indications for the treatment of chronic HCV infection and reasons to consider delaying HCV treatment in patients with HIV/HCV co-infection
Explain the reported safety and efficacy of currently available treatments for HCV in patients co-infected with HIV
List HCV/HIV drug combinations to avoid based on potential for drug-drug interactions
Select guidelines-recommended monitoring for patients being treated for HCV/HIV co-infection
Disclosure of Conflicts of Interest
Postgraduate Institute of Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Christian B. Ramers, MD, MPH, AAHIVS Assistant Medical Director – Research/Special Populations Director – Graduate Medical Education Family Health Centers of San Diego Assistant Clinical Professor of Medicine UC San Diego School of Medicine San Diego, CA
Dr. Ramers discloses the following: Consultant: Gilead Sciences, Bristol Myers-Squibb
Planners and Managers Disclosure
The PIM planners and managers, Trace Hutchinson, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBS, MSN, RN, and Jan Schultz, MSN, RN, CHCP, have nothing to disclose. The HealthHIV planners and managers Dana Cropper-Williams, Brian Hujdich, Sibyl Wilmont, and Michael Shankle, MPH, have nothing to disclose.
AMA PRA Category 1 Credit(s)TM
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and HealthHIV. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medication, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
To obtain credit, a score of 80% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.